COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pulmonology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic illness frequently leading to viral pneumonia and acute respiratory distress syndrome (ARDS).
• Corticosteroid efficacy in non-COVID-19 ARDS is debated, necessitating investigation in the context of the COVID-19 pandemic.

Purpose of the Study:

• To evaluate the effectiveness of early intravenous dexamethasone in adult patients with moderate to severe COVID-19-related ARDS.
• To assess the impact of dexamethasone on ventilator-free days within 28 days post-randomization.

Main Methods:

• A pragmatic, prospective, randomized, multicenter, open-label trial involving 350 patients with early-onset moderate or severe ARDS due to COVID-19.
• Patients were randomized to standard treatment plus early intravenous dexamethasone or standard treatment alone. Dexamethasone was administered for 5 days at 20mg daily, followed by 10mg daily for 5 days or until ICU discharge.

Main Results:

• The primary outcome was ventilator-free days within 28 days, defined as days alive and free from invasive mechanical ventilation.
• Secondary outcomes included 28-day all-cause mortality, clinical status at day 15, mechanical ventilation duration, Sequential Organ Failure Assessment (SOFA) scores, and ICU-free days.

Conclusions:

• Early intravenous dexamethasone administration is being evaluated for its effectiveness in improving recovery outcomes for patients with COVID-19-related ARDS.
• The study aims to provide evidence on the role of corticosteroids in managing severe respiratory compromise during the COVID-19 pandemic.